Biora Therapeutics Dirección

Dirección controles de criterios 2/4

Biora Therapeutics' El consejero delegado es Adi Mohanty , nombrado en Nov 2021, tiene un mandato de 2.08 años. la remuneración anual total es $3.52M , compuesta por 15.6% salario y 84.4% primas, incluidas acciones y opciones de la empresa. posee directamente 3.04% de las acciones de la empresa, por valor de $1.03M . La antigüedad media del equipo directivo y del consejo de administración es de 2.9 años y 2.5 años respectivamente.

Información clave

Adi Mohanty

Chief Executive Officer (CEO)

US$3.1m

Compensación total

Porcentaje del salario del CEO	18.3%
Permanencia del CEO	2.4yrs
Participación del CEO	0.4%
Permanencia media de la dirección	2.4yrs
Promedio de permanencia en la Junta Directiva	2.8yrs

Actualizaciones recientes de la dirección

Recent updates

Earnings Release: Here's Why Analysts Cut Their Progenity, Inc. (NASDAQ:PROG) Price Target To US$8.00

Mar 20

Is Progenity, Inc. (NASDAQ:PROG) Popular Amongst Insiders?

Mar 02

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Adi Mohanty en comparación con los beneficios de Biora Therapeutics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	US$3m	US$574k	-US$124m
Sep 30 2023	n/a	n/a	-US$122m
Jun 30 2023	n/a	n/a	-US$64m
Mar 31 2023	n/a	n/a	-US$52m
Dec 31 2022	US$4m	US$550k	-US$49m
Sep 30 2022	n/a	n/a	-US$118m
Jun 30 2022	n/a	n/a	-US$140m
Mar 31 2022	n/a	n/a	-US$176m
Dec 31 2021	US$10m	US$63k	-US$179m

Compensación vs. Mercado: Adi($USD3.52M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD738.70K).

Compensación vs. Ingresos: La compensación de Adi ha sido consistente con los resultados de la empresa en el último año.

CEO

Adi Mohanty (56 yo)

2.4yrs

Permanencia

US$3,139,017

Compensación

Mr. Aditya P. Mohanty, also known as Adi,M.B.A. serves as Chief Executive Officer and Director at Biora Therapeutics, Inc. (formerly known as Progenity, Inc.) since November 8, 2021. He served as the Co-Ch...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Aditya Mohanty	CEO & Director	2.4yrs	US$3.14m	0.45% $ 99.0k
Eric d'Esparbes	Chief Financial Officer	4.9yrs	US$1.60m	0.16% $ 36.3k
Clarke Neumann	Senior VP	9.6yrs	US$1.53m	0.14% $ 32.0k
Eric Fox	VP of Finance & Accounting & Treasurer	no data	sin datos	sin datos
Troy Seelye	Chief Information Officer	4.1yrs	sin datos	sin datos
George Gianakopoulos	Senior Vice President of Sales	4.5yrs	sin datos	sin datos
Robyn Hatton	Head of Human Resources	no data	sin datos	sin datos
Kevin Howe	Senior VP of Strategic Operations	no data	sin datos	sin datos
Sharat Singh	Head of Research	2yrs	sin datos	sin datos
Paul Shabram	Head of Technical Operations	2yrs	sin datos	sin datos
Ariella Kelman	Chief Medical Officer	less than a year	sin datos	sin datos
James Knight	Head of Business Development	less than a year	sin datos	sin datos

2.4yrs

Permanencia media

59yo

Promedio de edad

Equipo directivo experimentado: BIOREl equipo directivo de la empresa se considera experimentado (2.9 años de antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Aditya Mohanty	CEO & Director	2.4yrs	US$3.14m	0.45% $ 99.0k
Brian Kotzin	Independent Director	4.8yrs	US$185.11k	0.016% $ 3.5k
Anthony Lembo	Member of Clinical Advisory Board SIBO & Functional Bowel Disorders	no data	sin datos	sin datos
Geert D'Haens	Member of Inflammatory Bowel Disease Clinical Advisory Board	2.8yrs	sin datos	sin datos
Bruce Sands	Chairman of Inflammatory Bowel Disease Clinical Advisory Board	2.8yrs	sin datos	sin datos
Jeffrey Alter	Independent Chairman	5.3yrs	US$208.11k	0.018% $ 4.0k
Mark Pimentel	Member of Clinical Advisory Board - SIBO & Functional Bowel Disorders	no data	sin datos	sin datos
Lynne Powell	Independent Director	5.2yrs	US$163.11k	0.016% $ 3.5k
Severine Vermeire	Member of Inflammatory Bowel Disease Clinical Advisory Board	2.8yrs	sin datos	sin datos
Jill Howe	Independent Director	2.4yrs	US$180.11k	0.015% $ 3.3k
Satish Rao	Chair of Clinical Advisory Board-SIBO/Functional Bowel Disorders	no data	sin datos	sin datos
William Chey	Member of Clinical Advisory Board SIBO & Functional Bowel Disorders	no data	sin datos	sin datos

2.8yrs

Permanencia media

56yo

Promedio de edad

Junta con experiencia: BIORno se consideran experimentados ( 2.5 años de permanencia media), lo que sugiere un nuevo consejo.

Biora Therapeutics Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

High number of new and inexperienced directors

Biora Therapeutics, Inc.Appoints Bruce Sands as Chair of Its Clinical Advisory Board

Biora Therapeutics, Inc. Announces Board Appointment

High number of new and inexperienced directors

Progenity, Inc. Announces the Appointment of Paul Shabram as Senior Vice President, Technical Operations

Progenity, Inc. Announces Departure of Damon Silvestry

Recent updates

Biora Therapeutics, Inc. Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap Platform Development

Athyrium Capital Management Engages in Discussions with Biora Therapeutics

Biora Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $6.000003 million.

Biora Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $6.000003 million.

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Biora Therapeutics, Inc. to Report Q4, 2023 Results on Mar 26, 2024

New major risk - Share price stability

Biora Therapeutics, Inc. Announces Successful Completion of Single-Ascending Dose (Sad) Cohorts of Phase 1 Clinical Study of BT-600

Biora Therapeutics, Inc. Announces Initiation of Phase 1 Clinical Study of BT-600

Athyrium Capital Management Engages in Discussions with Biora Therapeutics

Biora Therapeutics Receives Non-Compliance Notice from Nasdaq

Biora Therapeutics, Inc. Announces FDA Clearance of IND Application for Drug/Device Combination BT-600 Targeting Treatment of Ulcerative Colitis

Consensus revenue estimates fall by 17%

Third quarter 2023 earnings released: US$4.89 loss per share (vs US$1.99 loss in 3Q 2022)

Biora Therapeutics, Inc. to Report Q3, 2023 Results on Nov 13, 2023

New minor risk - Share price stability

Biora Therapeutics Presents Data on the Biojet™ Systemic Oral Delivery Platform At the 59Th Annual Meeting of the European Association for the Study of Diabetes

Biora Therapeutics, Inc. (NasdaqGM:BIOR) acquired Interface Therapeutics Inc.

Biora Therapeutics Progresses Its BioJet™ Systemic Oral Delivery Platform

New major risk - Financial position

First half 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Biora Therapeutics, Inc. Announces New Patents Covering Its BioJet Systemic Oral Delivery Platform

Biora Therapeutics, Inc. Announces Clinical Device Performance Study Results for its NaviCap Targeted Oral Delivery Platform

Biora Therapeutics, Inc. to Report Q2, 2023 Results on Aug 14, 2023

An unknown large diagnostics company acquired Legacy Diagnostics Assets of Biora Therapeutics, Inc. (NasdaqGM:BIOR).

Biora Therapeutics Announces New Patents for Its NaviCap Targeted Oral Delivery Platform

Biora Therapeutics Presents Data on the BioJet Systemic Oral Delivery Platform at the American Diabetes Association 83rd Scientific Sessions

Biora Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $8 million.

First quarter 2023 earnings released: US$1.59 loss per share (vs US$1.98 loss in 1Q 2022)

Biora Therapeutics, Inc. to Report Q1, 2023 Results on May 15, 2023

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Biora Therapeutics Announces Improved Bioavailability Results for Its Systemic Delivery Platform

Biora Therapeutics Receives Compliance Letter from Nasdaq

Biora Therapeutics, Inc. Presents Data from Device Performance Study with Repeat Doses in Both Fasted and Fed States at Crohn’s & Colitis Congress

Biora Therapeutics, Inc. Receives Feedback from the United States Food and Drug Administration on Its Clinical Development Plans for Its Pgn-600 Program

Biora Therapeutics Receives Non-Compliance Notice from Nasdaq

Athyrium Capital Engages in Discussions with Biora Therapeutics

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus revenue estimates increase by 20%

Price target increased to US$5.00

High number of new and inexperienced directors

Biora Therapeutics, Inc. has completed a Follow-on Equity Offering.

Biora Therapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Biora Therapeutics, Inc. Shares Data from Device Performance Study in Ulcerative Colitis Patients

Biora Therapeutics, Inc. Shares Preclinical Data on Oral Delivery of Biologics At the 2022 Parenteral Drug Association Universe of Pre-Filled Syringes and Injection Devices Conference

Biora Therapeutics granted patent for oral delivery of GLP-1 receptor agonists

Biora Therapeutics, Inc.Appoints Bruce Sands as Chair of Its Clinical Advisory Board

Biora Therapeutics: Checking In On The Transformation

Second quarter 2022 earnings released: US$0.033 loss per share (vs US$0.65 loss in 2Q 2021)

Biora Therapeutics, Inc. Announces Successful Completion of Device Performance Study in Ulcerative Colitis Patients for Its Targeted Therapeutics Platform

Biora rallies 30%, highest since November on data for drug delivery device

Biora Therapeutics, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Biora Therapeutics Announces Successful Completion of Second Device Performance Study in Human Subjects for Its Targeted Therapeutics Platform

Biora Therapeutics, Inc. Announces Board Appointment

Biora Therapeutics Receives Non-Compliance Notice from Nasdaq

First quarter 2022 earnings released: US$0.079 loss per share (vs US$0.30 loss in 1Q 2021)

Biora Therapeutics, Inc. to Report Q1, 2022 Results on May 10, 2022

Price target increased to US$8.00

High number of new and inexperienced directors

Progenity, Inc. Announces the Appointment of Paul Shabram as Senior Vice President, Technical Operations

Price target increased to US$8.00

Full year 2021 earnings released: US$1.86 loss per share (vs US$3.83 loss in FY 2020)

Progenity, Inc. Announces Departure of Damon Silvestry

Progenity: Analyzing The Huge Paradigm Shift

Progenity: Transformation Raises Questions

Progenity, Inc. has completed a Follow-on Equity Offering in the amount of $40 million.

Price target increased to US$6.33

Independent Director John Bigalke has left the company

Progenity, Inc.(NasdaqGM:PROG) dropped from Russell 2500 Growth Index